Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy

European Journal of Cancer

Volumn 39, Issue 5, 2003, Pages 631-634

  Park, K ^a   Kim, J ^a   Lim, S ^a   Han, S ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Breast cancer; Chemotherapy; Chromogenic in situ hybridisation; Doxorubicin; HER2; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MEMBRANE PROTEIN; TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CHEMOSENSITIVITY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; HUMAN; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MASTECTOMY; PREOPERATIVE CARE; PRIORITY JOURNAL; TREATMENT OUTCOME; AGED; BREAST TUMOR; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; PROTO ONCOGENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DOXORUBICIN; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 0037333625     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00745-1     Document Type: Article

References (20)

1. Stern D.F., Hefferman P.A., Weinberg R.A. p185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Moll. Cell. Biol. 6:1986;1729-1740.
2. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer. correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. 235:1987;177-182.
3. Paik S., Hazan R., Fisher E.R.et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project. prognostic significance of erbB-2 protein overexpression in primary breast cancer J. Clin. Oncol. 8:1990;103-112.
4. Toikkanen S., Helin H., Isola J., Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer. a 30-yr follow-up J. Clin. Oncol. 10:1992;1044-1048.
5. Paik S., Bryant J., Park C.et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 90:1998;1361-1370.
6. Muss H.B., Thor A.D., Berry D.A.et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330:1994;1260-1266.
7. Gudkov A.V., Zelnick C.R., Kazarov A.R.et al. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc. Natl. Acad. Sci. USA. 90:1993;3231-3235.
8. Withoff S., Keith W.N., Knol A.J.et al. Selection of a subpopulation with fewer DNA topoisomerase IIα gene copies in a doxorubicin-resistant cell panel. Br. J. Cancer. 74:1996;502-507.
9. Zhou Z., Zwelling L.A., Kawakami Y.et al. Adenovirus-mediated human topoisomerase IIα gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res. 59:1999;4618-4624.
10. Jarvinen T.A.H., Tanner M., Rantanen V.et al. Amplification and deletion of Topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 156:2000;839-847.
11. Smith K., Houlbrook S., Greenall M., Carmichael J., Harris A.L. Topoisomerase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines. relationship to m-AMSA and mitoxantrone sensitivity Oncogene. 8:1993;933-938.
12. Kallioniemi O.P., Kallioniemi A., Kurisu W.et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridisation. Proc. Natl. Acad. Sci. USA. 89:1992;5321-5325.
13. Press M.F., Bernstein L., Thomas P.A.et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridisation. poor prognosis in node-negative breast carcinomas J. Clin. Oncol. 15:1997;2894-2904.
14. Tubbs R.R., Pettay J.D., Roche P.C., Stoler M.H., Jenkins R.B., Grogan T.M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy. apparent immunohistochemical false-positive do not get the message J. Clin. Oncol. 19:2001;2714-2721.
15. Tanner M., Gancberg D., Di Leo A.et al. Chromogenic in situ hybridization. A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am. J. Pathol. 157:2000;1467-1472.
16. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
17. Thor A.D., Berry D.A., Budman D.R.et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl. Cancer Inst. 90:1998;1346-1360.
18. Jarvinen T.A.H., Holli K., Kuukasjarvi T., Isola J. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer. 72:1998;2267-2273.
19. Bonadonna G., Valagussa P., Brambilla C.et al. Primary chemotherapy in operable breast cancer. eight-year experience at the Milan Cancer Institute J. Clin. Oncol. 16:1998;93-100.
20. Fisher B., Brown A., Mamounas E.et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer. findings from National Surgical Adjuvant Breast and Bowel Project B-18 J. Clin. Oncol. 15:1997;2483-2493.